# Wave Life Sciences to Present at Upcoming Investor Conferences Canonical URL: https://biopharmsignal.com/news/WVE/wave-life-sciences-to-present-at-upcoming-investor-conferences-c00fcf01 Ticker: WVE Company: Wave Life Sciences Source: Wave Life Sciences Published: 2026-06-01 12:30 EST ## Summary Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking... ## Article Body Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave’s management team are scheduled to participate in two upcoming investor conferences in June. 2026 Jefferies Global Healthcare Conference Date: Wednesday, June 3, 2026 Details: Paul Bolno, MD, MBA, President and CEO, will participate in an analyst-led fireside chat at 10:30 a.m. ET Goldman Sachs 47 th Annual Global Healthcare Conference Date: Monday, June 8, 2026 Details: Dr. Bolno will participate in an analyst-led fireside chat at 8:00 a.m. ET Live webcasts of the presentations can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events . Replays of these presentations will be archived and available on the site for a limited time following the event. About Wave Life Sciences Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM ® , combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn . Contact: Kate Rausch VP, Corporate Affairs and Investor Relations +1 617-949-4827 Investors: James Salierno Director, Investor Relations +1 617-949-4043 InvestorRelations@wavelifesci.com Media : Katie Sullivan Senior Director, Corporate Communications +1 617-949-2936 MediaRelations@wavelifesci.com ## Recent Company News - 2026-07-23 12:30 EST — [Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026](https://biopharmsignal.com/news/WVE/wave-life-sciences-second-quarter-2026-financial-results-scheduled-for-july-30-2-a9974bb9) — Source: Wave Life Sciences - 2026-07-07 20:15 EST — [Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation](https://biopharmsignal.com/news/WVE/wave-life-sciences-announces-singapore-court-hearing-to-be-held-on-july-14-2026--d94f52e6) — Source: Wave Life Sciences - 2026-06-24 12:30 EST — [Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases](https://biopharmsignal.com/news/WVE/wave-life-sciences-announces-initiation-of-phase-2a-portion-of-inlight-trial-of--2b38bb83) — Source: Wave Life Sciences - 2026-06-01 12:30 EST — [Wave Life Sciences to Present at Upcoming Investor Conferences](https://biopharmsignal.com/news/WVE/wave-life-sciences-to-present-at-upcoming-investor-conferences-c00fcf01) — Source: Wave Life Sciences - 2026-05-18 20:30 EST — [Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing](https://biopharmsignal.com/news/WVE/wave-life-sciences-announces-positive-update-on-restoraation-2-trial-wve-006-gal-3518234b) — Source: Wave Life Sciences ## Related News - 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a) - 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a) - 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2) - 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11) - 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)